Latest News

FDA Approves Tafasitamab in R/R Follicular Lymphoma
FDA Approves Tafasitamab in R/R Follicular Lymphoma

June 18th 2025

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.

ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL
ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL

May 20th 2025

Bexobrutideg Gains FDA Orphan Drug Status in Waldenström Macroglobulinemia
Bexobrutideg Gains FDA Orphan Drug Status in Waldenström Macroglobulinemia

March 18th 2025

Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL
Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL

January 17th 2025

Glofitamab Plus Polatuzumab Shows Durable Results in R/R LBCL
Glofitamab Plus Polatuzumab Shows Durable Results in R/R LBCL

December 10th 2024

More News